Page 1

BUSINESS HIGHLIGHTS FIRST-QUARTER 2025 RESULTS TOTAL COMPANY *Organic sales growth excludes impact of foreign exchange and the impact of discontinuing the ZonePerfect® product line in the Nutrition business. For full financial data and reconciliation of non-GAAP measures, please see our press release dated April 16, 2025, available at www.abbottinvestor.com. 1. On a GAAP basis, first-quarter Abbott sales increased 4.0%. 2. First-quarter 2025 GAAP diluted EPS was $0.76. 3. Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition related expenses, and foreign exchange, which could significantly impact Abbott’s results in accordance with GAAP. FORWARD-LOOKING STATEMENTS Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2024, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. ADJUSTED DILUTED EPS $1.09 2 SALES WORLDWIDE $10.4B +6.9% 1 ORGANIC* SALES GROWTH $2.1B DIAGNOSTICS $4.9B MEDICAL DEVICES $1.3B ESTABLISHED PHARMACEUTICALS $2.1B NUTRITION KEY BUSINESS UNITS ADJUSTED DILUTED EPS $5.05 to $5.25 7.5-8.5% ORGANIC* SALES GROWTH REAFFIRMED FULL-YEAR 2025 GUIDANCE 3 ADVANCING TREATMENT OF ATRIAL FIBRILLATION (AF ib) Obtained earlier-than-expected CE Mark for Volt™ Pulsed Field Ablation (PFA) System to treat patients battling AFib. Commercial PFA cases are underway in the EU, and we will expand use of Volt in EU markets in the second half of the year. Abbott is investing $500 million in Illinois and Texas. INVESTING IN U.S. MANUFACTURING, R&D Investments are projected to go live by the end of 2025. INNOVATING IN CARDIOVASCULAR CARE Initiated U.S. pivotal trial, TECTONIC, to evaluate the use of our investigational Coronary Intravascular Lithotripsy (IVL) System. Abbott’s Coronary IVL is designed to treat severe calcification in coronary arteries prior to implanting a stent.